Recent events
Recent events tied to this brand in public sources.
Back to profile51 entries · Page 2 of 3
2020
ConcertAI and Novartis announce oncology data collaboration
ConcertAI announced a multi-year collaboration with Novartis to advance real-world data and analytics for decision-making across Novartis' oncology pipeline and portfolio.
2020
Merck out-licenses M6495 program to Novartis
Merck announced an out-licensing agreement with Novartis for the M6495 anti-ADAMTS5 Nanobody program. Merck will receive an upfront payment and may receive milestone payments and royalties; Novartis will assume responsibility for development and commercialization.
2020
Novartis completes acquisition of Vedere Bio
Novartis acquired Vedere Bio; the transaction closed in September 2020. Vedere Bio shareholders received $150 million upfront and were eligible for up to $130 million in milestone payments.
2020
FDA approves Kesimpta for relapsing forms of multiple sclerosis
The US Food and Drug Administration approved Novartis' Kesimpta (ofatumumab) injection for treating relapsing forms of multiple sclerosis in adults.
2020
FDA approves Kesimpta for relapsing multiple sclerosis
The US Food and Drug Administration approved Novartis’s Kesimpta (ofatumumab) injection for adults with relapsing forms of multiple sclerosis, including clinically isolated syndrome, relapsing-remitting disease and active secondary progressive disease.
2020
US court upholds Gilenya dosage-regimen patent
The US District Court for the District of Delaware upheld the validity of the patent for the Gilenya dosage regimen, according to Novartis.
2020
Novartis settles US lawsuit over alleged doctor bribes
Novartis Pharmaceutical Corp. agreed to pay $678 million to settle a lawsuit over a speaker program that authorities alleged used payments, meals and other benefits to induce doctors to prescribe its products. The company admitted providing doctors cash, trips and lavish meals to encourage prescriptions, according to the government.
2020
Novartis agrees to settle U.S. fraud lawsuit
Novartis agreed to pay $678 million to settle a civil fraud lawsuit. The U.S. government accused the company of illegally providing doctors with cash payments and other perks to induce them to prescribe its drugs; the settlement resolves charges under the False Claims Act and an anti-kickback statute.
2020
AccessNow wins Novartis Innovation Prize
AccessNow won the Novartis Innovation Prize for Assistive Tech for MS. The first prize was worth USD 250,000 and recognized AccessNow's mobile app and web platform providing accessibility information about locations.
2020
FDA approves Ilaris for Still's disease
The U.S. Food and Drug Administration approved Novartis' Ilaris for treatment of active Still's disease, including adult-onset Still's disease.
2020
Federal Court fines GSK and Novartis over Osteo Gel marketing
The Federal Court ordered GlaxoSmithKline to pay $1.5 million and Novartis to pay $3 million after the companies admitted breaching Australian consumer law through their marketing of Osteo Gel between 2012 and 2017. The court found that the marketing misled consumers about the product's effectiveness compared with Emulgel.
2020
GSK and Novartis fined over Osteo Gel marketing
After GSK and Novartis admitted breaching Australian consumer law through their marketing of Osteo Gel between 2012 and 2017, a Federal Court justice ordered GSK to pay $1.5 million and Novartis to pay $3 million. The court found the conduct could have been avoided by making clear that the products had the same active ingredient.
2020
FDA approves Tabrecta for certain lung cancer patients
The U.S. Food and Drug Administration approved Novartis's Tabrecta for adult patients with non-small cell lung cancer that has spread to other parts of the body; the report says it is the first FDA-approved therapy for NSCLC with specific mutations.
2020
Novartis acquires Amblyotech
Novartis acquired Amblyotech’s outstanding shares and said it will develop the company's digital technology for amblyopia treatment.
2020
Novartis announces planned collaboration with Ubisoft on Amblyotech software
Alongside the acquisition announcement, Novartis said it planned to work with Ubisoft to develop Amblyotech software as a medical device, create games for it and conduct a proof-of-concept study planned for later in 2020.
2020
Novartis completes acquisition of Amblyotech
Novartis announced that it had completed its acquisition of software startup Amblyotech.
2020
Novartis and Aurobindo terminate planned Sandoz business sale
Novartis announced that it and Aurobindo Pharma USA mutually agreed to terminate their agreement for the sale of Sandoz's US generic oral solids and dermatology businesses after U.S. Federal Trade Commission approval was not obtained within the anticipated timelines. Sandoz will continue operating those businesses.
2020
Novartis donates hydroxychloroquine for COVID-19 trials
Novartis donated up to 130 million doses of hydroxychloroquine for use in investigational clinical trials for COVID-19. The article says the drug had not been approved for use as a COVID-19 treatment by the US FDA.
2020
Novartis recalled Sandimmune and Neoral 100 mg blister packages
Novartis recalled specified 100 mg Sandimmune and Neoral prescription drug blister packages because the packaging did not meet child-resistant requirements, posing a poisoning risk if young children swallowed the contents. No incidents or injuries were reported. Consumers were advised to secure the products and contact the firm for a free child-resistant pouch.
2020
BenchSci expands contract with Novartis
BenchSci announced that it had expanded its contract with Novartis; Novartis would be the first BenchSci customer to deploy the new AI-Assisted Reagent Selection product.